ASH 2012 - Atlanta - CML - Chronic Myeloid Leukemia
2012 ASH Annual Meeting and Exposition December 8-11, 2012
"iCMLf Forum" at ASH for physicians from emerging regions
CML Program
Saturday, December 8, 2012
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy II
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia - Therapy: Poster I
Sunday, December 9, 2012
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
Does the Stem Cell Survive Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia and, If So, How?
632. Chronic Myeloid Leukemia - Therapy: Aiming for Deep Response
632. Chronic Myeloid Leukemia - Therapy I
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia - Therapy: Poster II
Monday, December 10, 2012
632. Chronic Myeloid Leukemia - Therapy: Pharmacodynamic Markers and Novel Treatment Approaches
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia - Therapy: Poster III
901. Health Services and Outcomes Research: Poster III (abstract no 4234, 4236, 4237, 4260, 4274, 4279)
Tuesday, December 11, 2012
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy I
632. Chronic Myeloid Leukemia - Therapy II
Saturday, December 8, 2012
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy II
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster I
632. Chronic Myeloid Leukemia - Therapy: Poster I
Sunday, December 9, 2012
Chronic Myeloid Leukemia: The Pristine Paradigm for Successful Targeted Therapy
Does the Stem Cell Survive Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia and, If So, How?
632. Chronic Myeloid Leukemia - Therapy: Aiming for Deep Response
632. Chronic Myeloid Leukemia - Therapy I
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster II
632. Chronic Myeloid Leukemia - Therapy: Poster II
Monday, December 10, 2012
632. Chronic Myeloid Leukemia - Therapy: Pharmacodynamic Markers and Novel Treatment Approaches
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy: Poster III
632. Chronic Myeloid Leukemia - Therapy: Poster III
901. Health Services and Outcomes Research: Poster III (abstract no 4234, 4236, 4237, 4260, 4274, 4279)
Tuesday, December 11, 2012
631. Chronic Myeloid Leukemia - Biology and Pathophysiology, excluding Therapy I
632. Chronic Myeloid Leukemia - Therapy II
List of abstracts by number for CML
3, 31, 33, 34, 35, 36, 67, 68, 70, 163, 164, 166, 167, 168, 520, 691, 693, 694, 695,696, 759,
875, 907, 909, 911, 913, 914, 915, 917, 1215, 1234, 1339, 1360, 1415, 1662,1663, 1664, 1667,
1668, 1669, 1670, 1672, 1673, 1674, 1675, 1676, 1677, 1678, 1679,1680, 1681, 1682, 1683, 1685,
1686, 1687, 1688, 1689, 1690, 1691, 1693, 1712, 1903,1997, 2001, 2066, 2404, 2442, 2445, 2459,
2465, 2495, 2552, 2555, 2769, 2770, 2772,2774, 2775, 2776, 2777, 2780, 2781, 2782, 2783, 2784,
2787, 2788, 2789, 2790, 2792,2794, 2795, 2796, 2797, 2799, 2832, 3129, 3166, 3179, 3497, 3726,
3727, 3728, 3729,3730, 3733, 3735, 3738, 3740, 3741, 3742, 3743, 3744, 3745, 3746, 3747, 3749,
3750,3751, 3752, 3753, 3754, 3755, 3756, 3757, 3758, 3759, 3760, 3761, 3762, 3763, 3764,3766,
3767, 3768, 3769, 3770, 3771, 3772, 3773, 3774, 3776, 3777, 3778, 3780, 3781,3782, 3783, 3784,
3786, 3787, 3788, 4234, 4236, 4237, 4260, 4274, 4279
3, 31, 33, 34, 35, 36, 67, 68, 70, 163, 164, 166, 167, 168, 520, 691, 693, 694, 695,696, 759,
875, 907, 909, 911, 913, 914, 915, 917, 1215, 1234, 1339, 1360, 1415, 1662,1663, 1664, 1667,
1668, 1669, 1670, 1672, 1673, 1674, 1675, 1676, 1677, 1678, 1679,1680, 1681, 1682, 1683, 1685,
1686, 1687, 1688, 1689, 1690, 1691, 1693, 1712, 1903,1997, 2001, 2066, 2404, 2442, 2445, 2459,
2465, 2495, 2552, 2555, 2769, 2770, 2772,2774, 2775, 2776, 2777, 2780, 2781, 2782, 2783, 2784,
2787, 2788, 2789, 2790, 2792,2794, 2795, 2796, 2797, 2799, 2832, 3129, 3166, 3179, 3497, 3726,
3727, 3728, 3729,3730, 3733, 3735, 3738, 3740, 3741, 3742, 3743, 3744, 3745, 3746, 3747, 3749,
3750,3751, 3752, 3753, 3754, 3755, 3756, 3757, 3758, 3759, 3760, 3761, 3762, 3763, 3764,3766,
3767, 3768, 3769, 3770, 3771, 3772, 3773, 3774, 3776, 3777, 3778, 3780, 3781,3782, 3783, 3784,
3786, 3787, 3788, 4234, 4236, 4237, 4260, 4274, 4279
ASH 2012 NEWS
A CML Advocate's Perspective on News from ASH 2012 VIDEO
December 21, 2012, Patient Power
Study Brings Positive Results For the Most Resistant Types of CML VIDEO
December 12, 2012, Patient Power
Abstracts and notes on CML presentations - ASH 2012 Atlanta
December 11, 2012, CMLsupport
ASH: Higher Imatinib Exposures Associated with Better Chronic-Phase CML Outcomes
December 11, 2012, Chemotherapy advisor
ASH: Updated PACE Findings Uphold Ponatinib Benefit in CML and Ph+ ALL
December 11, 2012, Cancer Network
Learning about CML
December 11, 2012, Cure Today
Ponatinib Works in CML When Nothing Else Is Effective
December 11, 2012, Medscape Today News
Ariad rises on positive leukemia drug results
December 10, 2012, Boston Herald.com
Temple scientists target DNA repair to eradicate leukemia stem cells
December 9, 2012, MedicalXpress
RAD52-Dependent Synthetic Lethality Eradicates Leukemia Stem Cells
December 9, 2012, ASH 2012
Ariad drug proves effective in curbing chronic leukemia in study
December 9, 2012, Reuters
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
December 9, 2012, Science Codex
ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
December 9, 2012, ecancernews
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Studies Assess Role of Genetics, Modified Treatment Strategies to Improve Outcomes and Reduce Toxicity for Patients with Blood Cancers
December 8, 2012, The Sacramento Bee
Understanding Why MDS Patients Have Anemia VIDEO
December 8, 2012, Patient Power
What's Hot at ASH This Year?
December 3, 2012, Medscape Today
A CML Advocate's Perspective on News from ASH 2012 VIDEO
December 21, 2012, Patient Power
Study Brings Positive Results For the Most Resistant Types of CML VIDEO
December 12, 2012, Patient Power
Abstracts and notes on CML presentations - ASH 2012 Atlanta
December 11, 2012, CMLsupport
ASH: Higher Imatinib Exposures Associated with Better Chronic-Phase CML Outcomes
December 11, 2012, Chemotherapy advisor
ASH: Updated PACE Findings Uphold Ponatinib Benefit in CML and Ph+ ALL
December 11, 2012, Cancer Network
Learning about CML
December 11, 2012, Cure Today
Ponatinib Works in CML When Nothing Else Is Effective
December 11, 2012, Medscape Today News
Ariad rises on positive leukemia drug results
December 10, 2012, Boston Herald.com
Temple scientists target DNA repair to eradicate leukemia stem cells
December 9, 2012, MedicalXpress
RAD52-Dependent Synthetic Lethality Eradicates Leukemia Stem Cells
December 9, 2012, ASH 2012
Ariad drug proves effective in curbing chronic leukemia in study
December 9, 2012, Reuters
Novel therapeutic agents provide hope for patients with hard-to-treat blood disorders
December 9, 2012, Science Codex
ASH 2012: Ponatinib for CML and Philadelphia chromosome-positive acute lymphoblastic leukaemia
December 9, 2012, ecancernews
Is going for cure in chronic myeloid leukemia possible and justifiable?
December 8, 2012, Hematology
Studies Assess Role of Genetics, Modified Treatment Strategies to Improve Outcomes and Reduce Toxicity for Patients with Blood Cancers
December 8, 2012, The Sacramento Bee
Understanding Why MDS Patients Have Anemia VIDEO
December 8, 2012, Patient Power
What's Hot at ASH This Year?
December 3, 2012, Medscape Today
Forums and Patient associations'reports
ASH 2012 News by the CML Advocates Network
ASH 2012 by Cmlsupport (UK)
ASH 2012 by AsianCMLSupportGroup
ASH 2012 by the National CML Society (US)
ASH Reports 2012 by CML Society of Canada
ASH 2012 News by the CML Advocates Network
ASH 2012 by Cmlsupport (UK)
ASH 2012 by AsianCMLSupportGroup
ASH 2012 by the National CML Society (US)
ASH Reports 2012 by CML Society of Canada
SOME INTERESTING ABSTRACTS FOR CML
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results
Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells
Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease
Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib
Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307
Progressive Peripheral Arterial Occlusive Disease and Other Vascular Events During Nilotinib Therapy in Chronic Myeloid Leukemia
Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ΕΝΕSΤnd
Effects of Tyrosine Kinase Inhibitors On Spermatogenesis and Pituitary Gonadal Axis in Males with Chronic Myeloid Leukemia
A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV
Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial
Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib
Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy
Activation Levels of Natural Killer Cells and CD8+ T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients
Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML
Patient Preferences for Stopping Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results
Chaetocin Exhibits Anti-Leukemia Activity Against Chronic Myeloid Leukemia Stem Cells
Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease
Sabutoclax, a Novel Pan BCL2 Family Inhibitor, Sensitizes Dormant Blast Crisis Chronic Myeloid Leukemia Stem Cells to Dasatinib
Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307
Progressive Peripheral Arterial Occlusive Disease and Other Vascular Events During Nilotinib Therapy in Chronic Myeloid Leukemia
Dasatinib Therapy Affects Bone Homeostasis in Patients with Chronic Myelogenous Leukemia in Chronic Phase Independently of Molecular Response
Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ΕΝΕSΤnd
Effects of Tyrosine Kinase Inhibitors On Spermatogenesis and Pituitary Gonadal Axis in Males with Chronic Myeloid Leukemia
A Sensitive Replicate RQ-PCR of BCR ABL Transcripts Suggests That A Large Portion of Long Term Post Allogeneic SCT CML Patients Are in Deep MR and May Therefore Be Cured From Their Disease
Complete Molecular Remission (CMR 4.5) of CML Is Induced Faster by Dose – Optimized Imatinib and Predicts Better Survival - Results From the Randomized CML-Study IV
Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update
Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update
Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance or Intolerance to BCR-ABL Tyrosine Kinase Inhibitors: Radotinib Phase 2 Clinical Trial
Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center
Clinical Significance of Deeper Molecular Responses with Four Modalities of Tyrosine Kinase Inhibitors As Frontline Therapy for Chronic Myeloid Leukemia
Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib
Fatigue Is the Major Aspect Compromising Health-Related Quality of Life of Chronic Myeloid Leukemia Patients Receiving Long-Term Imatinib Therapy
